Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases

被引:261
作者
Fressinaud, E
Veyradier, A
Truchaud, F
Martin, I
Boyer-Neumann, C
Trossaert, M
Meyer, D
机构
[1] Hop Bicetre, INSERM, U143, F-94275 Le Kremlin Bicetre, France
[2] CHU Hotel Dieu, Hematol Lab, Nantes, France
[3] Hop Antoine Beclere, Hematol Lab, Clamart, France
关键词
D O I
10.1182/blood.V91.4.1325
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have evaluated the performance of a new analyzer using high shear stress, the PFA-100 (Platelet Function Analyzer, Dade International, Massy, France), for screening of patients with von Willebrand disease (vWD). Whole citrated blood is aspirated through a capillary to the central aperture of a membrane coated with collagen and with a platelet agonist (either epinephrine or adenosine diphosphate [ADP]). The time required to obtain occlusion of the aperture by a platelet plug is defined as the closure time (CT). We studied 60 patients with different types of vWD and 96 normal subjects. Fourteen subjects with hemophilia and 15 patients with a platelet disorder were also analyzed. When omitting results from two patients with type 2N, the 58 other patients with type 1, type 2A, type 2B, type 3, or acquired vWD all exhibited an abnormal occlusion with collagen-ADP (sensitivity, 100%) and 56 of 58 had an abnormal CT with collagen-epinephrine (sensitivity, 96.5%). Only two patients with mild type 1 were not detected with collagen-epinephrine. In comparison, the bleeding time (BT) was normal in 20 patients: 17 with type 1, two with type 2A, and one with acquired vWD (sensitivity, 65.5%). The specificity of the PFA-100 was over 95% with both types of cartridges. Thus, the analyzer Is well adapted to routine testing, as it has the advantages of simplicity and ease of execution, and demonstrates a high sensitivity, clearly superior to that of BT, for the screening of patients with vWD. (C) 1998 by The American Society of Hematology.
引用
收藏
页码:1325 / 1331
页数:7
相关论文
共 23 条
  • [1] FRESSINAUD E, 1993, CR ACAD SCI III-VIE, V316, P1260
  • [2] GILL JC, 1987, BLOOD, V69, P1691
  • [3] GINSBURG D, 1993, THROMB HAEMOSTASIS, V69, P177
  • [4] CHARACTERIZATION OF THE UNIQUE MECHANISM MEDIATING THE SHEAR-DEPENDENT BINDING OF SOLUBLE VON-WILLEBRAND-FACTOR TO PLATELETS
    GOTO, S
    SALOMON, DR
    IKEDA, Y
    RUGGERI, ZM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) : 23352 - 23361
  • [5] GRALNICK HR, 1995, WILLIAMS HEMATOLOGY, P1458
  • [6] THE ROLE OF VONWILLEBRAND-FACTOR AND FIBRINOGEN IN PLATELET-AGGREGATION UNDER VARYING SHEAR-STRESS
    IKEDA, Y
    HANDA, M
    KAWANO, K
    KAMATA, T
    MURATA, M
    ARAKI, Y
    ANBO, H
    KAWAI, Y
    WATANABE, K
    ITAGAKI, I
    SAKAI, K
    RUGGERI, ZM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (04) : 1234 - 1240
  • [7] *IT WORK GROUP, 1977, BRIT J HAEMATOL, V35, P101
  • [8] KUNDU SK, 1995, SEMIN THROMB HEMOST, V21, P106
  • [9] Characterization of an in vitro platelet function analyzer, PFA-100(TM)
    Kundu, SK
    Heilmann, EJ
    Sio, R
    Garcia, C
    Ostgaard, RA
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1996, 2 (04) : 241 - 249
  • [10] MAMMEN EF, 1995, SEMIN THROMB HEMOST, V21, P113